Letters Pioglitazone use and risk of bladder cancer

Don’t dismiss pioglitazone on basis of uncertain risk

BMJ 2016; 354 doi: https://doi.org/10.1136/bmj.i3667 (Published 06 July 2016) Cite this as: BMJ 2016;354:i3667
  1. Alison Gallagher, consultant physician and diabetologist1,
  2. Peter H Winocour, consultant physician and diabetologist1
  3. on behalf of the Association of British Clinical Diabetologists
  1. 1Association of British Clinical Diabetologists, ABCD Secretariat, PO Box 2927, Malmesbury SN16 0WZ, UK
  1. alison.gallagher{at}uhl-tr.nhs.uk

Tuccori and colleagues conclude that the use of pioglitazone is associated with increased risk of bladder cancer.1 However, in this study pioglitazone and non-pioglitazone users were not matched and, despite adjustment, pioglitazone users were older, had type 2 diabetes for longer, and had worse glycaemic control than non-pioglitazone users.2

It is worrying …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe